fluoxetine has been researched along with Fatty Liver, Nonalcoholic in 4 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have previously shown in rats that fetal and neonatal exposure to the SSRI antidepressant fluoxetine results in metabolic perturbations including increased hepatic triglyceride content; a hallmark of non-alcoholic fatty liver disease (NAFLD)." | 7.85 | Increased incidence of non-alcoholic fatty liver disease in male rat offspring exposed to fluoxetine during fetal and neonatal life involves the NLRP3 inflammasome and augmented de novo hepatic lipogenesis. ( De Long, NE; Hardy, DB; Holloway, AC; Ma, N, 2017) |
| " We have previously shown in rats that fetal and neonatal exposure to the SSRI antidepressant fluoxetine results in metabolic perturbations including increased hepatic triglyceride content; a hallmark of non-alcoholic fatty liver disease (NAFLD)." | 3.85 | Increased incidence of non-alcoholic fatty liver disease in male rat offspring exposed to fluoxetine during fetal and neonatal life involves the NLRP3 inflammasome and augmented de novo hepatic lipogenesis. ( De Long, NE; Hardy, DB; Holloway, AC; Ma, N, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayyash, A | 2 |
| Holloway, AC | 4 |
| De Long, NE | 2 |
| Hardy, DB | 2 |
| Ma, N | 1 |
| Barry, EJ | 1 |
| Pinelli, C | 1 |
| Wood, GA | 1 |
| Morrison, KM | 1 |
| Taylor, VH | 1 |
| Gerstein, HC | 1 |
4 other studies available for fluoxetine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Fluoxetine-induced hepatic lipid accumulation is mediated by prostaglandin endoperoxide synthase 1 and is linked to elevated 15-deoxy-Δ
Topics: Cyclooxygenase 2; Depressive Disorder, Major; Fluoxetine; Humans; Non-alcoholic Fatty Liver Disease; | 2022 |
Fluoxetine-induced hepatic lipid accumulation is linked to elevated serotonin production.
Topics: Cell Line, Tumor; Fluoxetine; Humans; Lipid Metabolism; Liver; Non-alcoholic Fatty Liver Disease; Se | 2021 |
Increased incidence of non-alcoholic fatty liver disease in male rat offspring exposed to fluoxetine during fetal and neonatal life involves the NLRP3 inflammasome and augmented de novo hepatic lipogenesis.
Topics: Animals; Animals, Newborn; Epigenesis, Genetic; Female; Fluoxetine; Incidence; Inflammasomes; Lipoge | 2017 |
Antenatal exposure to the selective serotonin reuptake inhibitor fluoxetine leads to postnatal metabolic and endocrine changes associated with type 2 diabetes in Wistar rats.
Topics: Adiposity; Animals; Blood Glucose; Chemical and Drug Induced Liver Injury; Chemokine CCL2; Diabetes | 2015 |